Investors are carefully monitoring
Blackstone Inc. (BX), as it has made significant moves in the bio-tech market recently. Its Q2 earnings recorded a modest rise due to gains in private equity and credit. Additionally,
Blackstone also acquired Tropical Smoothie Cafe and completed a massive A$24B transaction to acquire AirTrunk. It also capitalized on the robust growth of the private credit business outside the US, championing a $30 Trillion opportunity. Despite all this, some investors like Beaumont Financial Advisors and Artemis Investment Management have decided to reduce their stakes in
Blackstone. Furthermore, Blackstone's recent poor short interest and downgrade at Piper has raised some questions. Regardless, the company's strong forward outlook and investment strategies are anticipated to bolster its reputation. Blackstone is looking to raise at least $10 billion in new Asian PE fund and sees Asia as a 'growth engine'. The company has also announced a collaboration with Moderna's Influenza Program, signaling its interests in the healthcare sector. Looking positively at Blackstone's fundamental resilience, Morgan Stanley gave it a new price target of $177.00.
Blackstone BX News Analytics from Wed, 14 Feb 2024 08:00:00 GMT to Sat, 12 Oct 2024 09:47:22 GMT -
Rating 2
- Innovation -5
- Information 8
- Rumor -3
